Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers October 22, 2017
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - October 22, 2017

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

9/22/17 - 3SBio Accelerates Expansion of its Global Biologics Platform by Acquiring the Canadian Biomanufacturing Business of Therapure
By a News Reporter-Staff News Editor at Drug Week 3 SBio Inc., a leading Chinese biopharmaceutical company, is pleased to announce that it has entered into a Shareholder Agreement with CPE Funds, pursuant to which a Joint Venture shall be established. On September 1st, the JV entered into an Asset Purchase Agreement with Canada- based biologics m
9/22/17 - 50 Ways to Cut Your Health Care Costs
Even with good insurance from your employer, you're most likely paying a larger share of your medical expenses than in the past $11,600 for the average family in 2017, according to the Milliman Medical Index. The median deductible for in-network care charged by large employers is $1,300 for employee-only coverage and $3,000 for families, accordin
9/22/17 - 65 OM OTC Meds
Office Address: Department of Veterans Affairs; National CMOP; 3450 S. 4th St. Trafficway; Leavenworth KS 66048-5581. Description: Department of Veterans Affairs. DMS Pharmaceutical Group, Inc. $185,169.60.
9/22/17 - Aeterna Zentaris Announces Departure of Vice President, Finance & Chief Accounting Officer
By a News Reporter-Staff News Editor at Drug Week Aeterna Zentaris Inc. announced the departure of the Company's Vice President, Finance& Chief Accounting Officer, Genevieve Lemaire, effective on or before September 30, 2017. About Aeterna Zentaris Inc. Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing and commercial
9/22/17 - Amerigen believes that it is a first applicant to file an Abbreviated New Drug Application "ANDA" for certain strengths of Namzaric containing a...
By a News Reporter-Staff News Editor at Drug Week Amerigen Pharmaceuticals Limited announced that, based on the August 7th, 2017 update to the U.S. Food& Drug Administration's online databasea, the Company believes that it is a first applicant to file an Abbreviated New Drug Application for Namzaric 7/ 10 b and 21/ 10 c containing a "Paragraph
9/22/17 - An Application for the Trademark "FREESTYLE INSULINX" Has Been Filed by Abbott Laboratories
By a News Reporter-Staff News Editor at Health& Medicine Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a trademark application has been made for "FREESTYLE INSULINX" by Michele H. Bowman, representing Abbott Laboratories. The owner/registrar information for this application is: Michele H. Bowman, Abbot
9/22/17 - ANI Pharmaceuticals Announces Approval and Launch of Oxycodone Hydrochloride Oral Solution, 100 mg/5mL
By a News Reporter-Staff News Editor at Drug Week ANI Pharmaceuticals, Inc. announced that it has received approval from the U.S. Food and Drug Administration of its Abbreviated New Drug Application for Oxycodone Hydrochloride Oral Solution USP, 100 mg/5 mL. The current annual U.S. market for this product is approximately $14.5 million, according
9/22/17 - Aquavit's iMicrotox IMX-001 Study Receives IRB Approval
By a News Reporter-Staff News Editor at Health& Medicine Week Aquavit Pharmaceuticals announced that it has received a green light from the IRB, to conduct in-depth research for microchannel application of neurotoxins in the peri-orbital region. This study includes the three currently FDA approved neurotoxins to be administered through AQT-001,..
9/22/17 - Biosimilars take center stage at 2017 ACR/ARHP Annual Meeting
By a News Reporter-Staff News Editor at Drug Week ATLANTA- "Biosimilars: To Switch or Not to Switch?" Jonathan Kay, Professor of Medicine at the University of Massachusetts, and Dr. Roy Fleischmann, Clinical Professor at the University of Texas Southwestern Medical Center.
9/22/17 - BioSpecifics Technologies Corp. to Present at Two Upcoming September Conferences
By a News Reporter-Staff News Editor at Drug Week BioSpecifics Technologies Corp., a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX in the U.S. and Xiapex in Europe, announced that BioSpecifics' President, Tom Wegman, will pre
9/22/17 - Bioventus Receives US FDA Approval for DUROLANE
By a News Reporter-Staff News Editor at Health& Medicine Week Bioventus, a global leader in orthobiologic solutions, announced it has received US FDA approval for DUROLANE, a single-injection, hyaluronic acid product used for joint lubrication in the treatment of pain associated with knee osteoarthritis. "More than 20 million Americans are affli
9/22/17 - Blacksburg firm snags funding Blacksburg biotech snags $10 million investment to push new drug into clinical trials
Landos Biopharma, a new Blacksburg startup, burst out of the gate on Thursday with $10 million in venture funding to begin clinical trials of a potentially breakthrough drug. The company was founded earlier this year by Virginia Tech's Josep Bassaganya-Riera, a researcher with a track record of spinout companies. Landos launched earlier this year a
9/22/17 - Blacksburg firm snags funding
Landos Biopharma, a new Blacksburg startup, burst out of the gate on Thursday with $10 million in venture funding to begin clinical trials of a potentially breakthrough drug. The company was founded earlier this year by Virginia Tech's Josep Bassaganya-Riera, a researcher with a track record of spinout companies. Landos launched earlier this year a
9/22/17 - Can-fite Biopharma Ltd. Files SEC Form 6-K, Report of Foreign Issuer [Rules 13A-16 And 15D-16]: (Sept. 1, 2017)
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Can-fite Biopharma Ltd. was posted on September 1, 2017. The SEC file number is 0001213900-17-009360.. A U.S. Securities and Exchange Commission filing is a for
9/22/17 - CASI Pharmaceuticals To Present At The Annual Rodman & Renshaw Global Investment Conference
By a News Reporter-Staff News Editor at Drug Week CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs announces it will present at the 19th Annual Rodman& Renshaw Global Investment Conference, sponsored by H.C. Wainwright& Co., LLC. The conference is being he
9/22/17 - Cti Biopharma Corp. Files SEC Form 8-K, Current Report: (Aug. 31, 2017)
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Cti Biopharma Corp. was posted on August 31, 2017. The SEC file number is 0000891293-17-000093.. A U.S. Securities and Exchange Commission filing is a formal do
9/22/17 - Data on Drug Delivery Systems Detailed by Researchers at Leiden University (Characterization of drug delivery particles, produced by supercritical...
Data on Drug Delivery Systems Detailed by Researchers at Leiden University. Our news journalists obtained a quote from the research from Leiden University, "In particular, characterization techniques for particle size distribution and morphology, drug loading and release, structure of matrix components, potency, porosity, particle surface chemistry
9/22/17 - Dicerna to Present at Rodman & Renshaw 19th Annual Global Investment Conference
By a News Reporter-Staff News Editor at Drug Week Dicerna Pharmaceuticals, Inc., a leading developer of investigational ribonucleic acid interference therapeutics, announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the Rodman& Renshaw 19th Annual Global Investment Conference on Tuesday, September 12
9/22/17 - DR REDDY'S UNIT CLEARED BY USFDA
The Custom Pharmaceutical Services facility of Dr Reddy's Laboratories Limited at its Technology Development Centre, Miyapur has obtained clearance from the US Food and Drug Administration audit. The audit of the facility was completed with zero observations. The company has also received an Establishment Inspection Report from the USFDA for its...
9/22/17 - Drug Maker Aegerion Agrees to Plead Guilty; Will Pay More Than $35 Million to Resolve Criminal Charges and Civil False Claims Allegations
Aegerion Pharmaceuticals Inc., a Cambridge, Massachusetts- based subsidiary of Novelion Therapeutics Inc., has agreed to plead guilty to charges relating to its prescription drug, Juxtapid, the Justice Department announced today. "Aegerion has agreed to plead guilty to breaking the law.The Justice Department will continue to ensure that taxpayers
9/22/17 - European Commission Approves Bavencio (Avelumab) for Metastatic Merkel Cell Carcinoma
Pfizer, a pharmaceutical company, issued the following news release:. Merck KGaA, Darmstadt, Germany, and Pfizer Inc. today announced that the European Commission has granted marketing authorization for BAVENCIO as a monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma, a rare and aggressive skin cancer.
9/22/17 - Experts challenged on role of food in medicare
Medics have been urged to teach their patients the role of food as medicine for combating daily health challenges, especially oxidative stress. Medical Director, Lindabel Medical Centre, Surulere, Lagos, Dr David Abia-Okon stated this at this year's Annual General Meeting and Scientific Conference of the Lagos Chapter of Association of General and
9/22/17 - Findings from Laboratory of Immunology in Pharmacy and Pharmacology Reported (Immunogenicity assessment during the development of protein...
Findings from Laboratory of Immunology in Pharmacy and Pharmacology Reported. Funders for this research include Chief Scientist's Challenge Grant, Center for Biologics Evaluation and Research at the US Food and Drug Administration. The news correspondents obtained a quote from the research from the Laboratory of Immunology, "The science and technol
9/22/17 - Findings from Qingdao Agricultural University Yields New Findings on Vaccines (Microneedle Patches as Drug and Vaccine Delivery Platform)
By a News Reporter-Staff News Editor at Drug Week Current study results on Immunization- Vaccines have been published. According to news reporting originating in Qingdao, People's Republic of China, by NewsRx journalists, research stated, "Transcutaneous delivery is the ideal method for delivering therapeutic reagents or vaccines into skin.
9/22/17 - Findings from University College Update Understanding of Drug Delivery Systems (3D printed tablets loaded with polymeric nanocapsules: An innovative...
By a News Reporter-Staff News Editor at Drug Week Investigators publish new report on Drugs and Therapies- Drug Delivery Systems. According to news reporting from London, United Kingdom, by NewsRx journalists, research stated, "The generation of multi-functional drug delivery systems, namely solid dosage forms loaded with nano-sized carriers, rem
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415